This letter is dedicated to honoring all of the significant others who have been a part of the Ketamine Wellness Center’s community.
Ketamine Infusion Therapy
Including revealing yet more failings in current care and services A February 2022 article in Medpage Today covered the startling impact on mental health conditions resulting from the COVID epidemic. A study in the British Medical Journal has found mental health-related drug prescriptions are up by a shocking 86%. Of those who overcame COVID-19 infection …
Message from the CEO If you’re anything like me, the holidays already seem like a happy memory. I hope yours were wonderful; and, let me wish a Happy New Year to all our KWC patients and families. Here at KWC we’re all about our resolutions for 2022, and have already kept two! Ketamine Wellness Centers Salt Lake City …
More than 40 million Americans are living with a substance use disorder (SUD) according to the 2020 survey from the Substance Abuse and Mental Health Services Administration (SAMHSA) – just 11% of these people in need receive any kind of treatment. Ketamine has been linked with better outcomes in substance misuse treatment when used along with behavioral and motivational therapy.
Ketamine Wellness Centers (KWC) the largest ketamine therapy provider in the United States, announces two new partnerships with the Veterans Affairs Community Care Networks (VA-CCN) of Illinois and Minnesota. The partnership will allow KWC to offer ketamine treatments to veterans at no out-of-pocket cost at the KWC locations in Chicago, IL, and Minneapolis, MN.
Pumpkin-spiced everything is upon us! It’s hard to believe the holidays are right around the corner. Over the last 11 years, I have had the opportunity to share some announcements as Ketamine Wellness Centers grew and changed. Once again I have the privilege to announce one of our biggest changes to date.
Ketamine is one of the most widely used and safest anesthetics in the world according to the World Health Organization who list it as an essential medicine. Researchers at Yale have been studying low-dose ketamine since 2000 in controlled clinic settings for patients with severe depressions unresponsive to other antidepressants.